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Tumor necrosis factor receptor-associated fac-
tor 3 (TRAF3) is an adaptor protein that directly
binds to a number of receptors of the tumor
necrosis factor receptor (TNF-R) superfamily.
Despite in vitro evidence that TRAF3 plays di-
verse roles in different cell types, little is known
about the in vivo functions of TRAF3. To ad-
dress this gap in knowledge and to circumvent
the early lethal effect of TRAF3 null mutations,
we generated conditional TRAF3-deficient mice.
B-cell-specific Traf3/ mice displayed severe
peripheral B cell hyperplasia, which culminated
in hyperimmunoglobulinemia and increased T-
independent antibody responses, splenomeg-
aly and lymphadenopathy. Resting splenic B
cells from these mice exhibited remarkably
prolonged survival ex vivo independent of B
cell activating factor and showed increased
amounts of active nuclear factor-kB2 but de-
creased amounts of nuclear protein kinase Cd.
Furthermore, these mice developed autoim-
mune manifestations as they aged. These find-
ings indicate that TRAF3 is a critical regulator of
peripheral B cell homeostasis andmay be impli-
cated in the regulation of peripheral self-toler-
ance induction.
INTRODUCTION
Tumor necrosis factor receptor-associated factor 3
(TRAF3), a member of the TRAF family of cytoplasmic
adaptor proteins, is exploited for signaling by a number
of receptors of the tumor necrosis factor receptor (TNF-R)
superfamily as well as the Epstein-Barr virus (EBV)-en-
coded oncoprotein latent membrane protein 1 (LMP1)
(Bishop, 2004; Miller et al., 2006; Wajant et al., 2001).
TRAF3 directly binds to almost all TNF-R-superfamilyreceptors that do not contain death domains, including
CD40, receptors for B cell activating factor (BAFF) and
a proliferation-inducing ligand (APRIL), lymphotoxin b re-
ceptor (LTbR), CD27, CD30, receptor activator of NF-kB
(RANK), herpesvirus entry mediator (HVEM), ectodyspla-
sin A receptor (EDAR), X-linked ectodermal dysplasia re-
ceptor (XEDAR), 4-1BB, OX-40, and glucocorticoid-in-
duced TNF-R-related gene (GITR). Among these, BAFF
receptors and CD40 are pivotal in the physiology of B lym-
phocytes, the only mammalian cell type that can produce
antibodies.
BAFF is a crucial B cell survival factor, binding to the fol-
lowing three receptors of the TNF-R superfamily: BCMA,
TACI, and BAFF-R (Mackay et al., 2003; Miller et al.,
2006). TACI and BCMA are also bound by APRIL, a TNF
family member closely related to BAFF. Interestingly,
BAFF-R appears to be the sole mediator of BAFF-medi-
ated B cell-survival signals. Only BAFF-R-deficient mice
recapitulate the phenotype of BAFF-deficient mice, which
display almost complete loss of mature B lymphocytes
and marginal zone B cells and deficiency in mounting
T-dependent humoral responses (Schiemann et al., 2001;
Shulga-Morskaya et al., 2004). In contrast, B cell matura-
tion in BCMA-deficient, TACI-deficient, and BCMA and
TACI double-deficient mice is normal or enhanced
(Mackay et al., 2003; Shulga-Morskaya et al., 2004). The
two predominant signaling pathways initiated by BAFF
and BAFF-R interactions shown to promote B cell
survival are the alternative NF-kB (NF-kB2) pathway and
inhibition of protein kinase Cd (PKCd) nuclear transloca-
tion (Claudio et al., 2002; Mecklenbrauker et al., 2004).
To date, the only TRAF protein shown to directly interact
with BAFF-R is TRAF3 (Miller et al., 2006). A recent study
reported that mutation of the putative TRAF-binding motif
of BAFF-R abolishes its interaction with TRAF3 and its
ability to induce NF-kB2 activation in the mouse B cell
line M12, suggesting that TRAF3 is critical for BAFF-R-
mediated NF-kB2 activation in B cells (Morrison et al.,
2005).
CD40 and its ligand CD154 are obligatory for T cell-
dependent B cell activation, regulating formation of germi-
nal centers, immunoglobulin (Ig) isotype switching, andImmunity 27, 253–267, August 2007 ª2007 Elsevier Inc. 253
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et al., 2004). All these processes are severely impaired in
CD40-deficient or CD154-deficient mice or in human pa-
tients carrying CD40LG mutations (Grammer and Lipsky,
2000). Upon ligand binding, CD40 recruits TRAF1,
TRAF2, TRAF3, TRAF5, and TRAF6 directly or indirectly
to its signaling complex (Bishop, 2004; Grammer and
Lipsky, 2000; Xie et al., 2006). TRAF recruitment in turn
triggers multiple signaling cascades, including activation
of kinases (such as p38, JNK, ERK, and Akt) and transcrip-
tion factors (such as NF-kB and AP-1). This ultimately
leads to proliferation, upregulation of adhesion and costi-
mulatory molecules, and secretion of antibodies and cyto-
kines (Bishop, 2004; Grammer and Lipsky, 2000). By using
Traf3/ B cell lines, we previously showed that CD40-
induced JNK activation and antibody secretion are en-
hanced in the absence of TRAF3 (Xie et al., 2004). Con-
versely, signaling by LMP1, the viral oncogenic mimic of
CD40, is defective in Traf3/ B cells (Xie and Bishop,
2004; Xie et al., 2004). LMP1-induced activation of JNK,
p38, and NF-kB and upregulation of CD23 and CD80, as
well as antibody secretion, are profoundly impaired by
TRAF3 deficiency (Xie and Bishop, 2004; Xie et al.,
2004). Thus, CD40 and LMP1 use TRAF3 in sharply differ-
ent ways in B cells.
In addition to directly interacting with the TNF-R super-
family receptors, TRAF3 has recently been found to be in-
volved in production of type I interferon and IL-10 induced
by Toll-like receptors (TLRs) in macrophages and den-
dritic cells through association with TRIF, an adaptor pro-
tein for TLRs (Hacker et al., 2006; Oganesyan et al., 2006).
Taken together, these in vitro observations indicate that
TRAF3 can play important and diverse roles depending
on the specific interacting receptor and cellular context.
This warrants further in vivo investigation so that the phys-
iological functions of TRAF3 in the intact animal can be un-
derstood.
Mice genetically deficient in the gene encoding TRAF3
die within 10 days after birth, demonstrating the ubiqui-
tous and critical developmental functions of TRAF3 (Xu
et al., 1996). However, assessment of specific functions
of TRAF3 in the immune system and in signaling by the
TNF-R superfamily or TLRs in tissues of adult mice is
compromised by the early lethality of Traf3/ mice. To
circumvent this problem, we employed a conditional
gene targeting strategy through Cre-loxP-mediated re-
combination and generated conditional TRAF3-deficient
mice, which allow the deletion of the Traf3 gene in spe-
cific cell types or tissues. We found that specific ablation
of the gene encoding TRAF3 in the B cell lineage led to
remarkably prolonged B cell survival and greatly ex-
panded B cell compartments in secondary lymphoid or-
gans with markedly increased numbers of T2 transitional,
marginal zone and follicular B cells. This culminated in
splenomegaly and lymphadenopathy, hyperimmunoglo-
bulinemia, and autoimmune reactivity. Our findings reveal
a critical role for TRAF3 in regulating peripheral B cell
homeostasis and implicate TRAF3 in peripheral self-toler-
ance induction.254 Immunity 27, 253–267, August 2007 ª2007 Elsevier Inc.RESULTS
Conditional Deletion of the Traf3 Gene
By using a conditional gene targeting approach, we gen-
erated mouse embryonic stem cells and a new mouse
strain in which the Traf3 gene is modified with insertions
of two loxP sequences, recognition sites of the DNA re-
combinase Cre, into the introns flanking the first two cod-
ing exons of Traf3 (Figures S1 and S2 in the Supplemental
Data available online). Such ‘‘flox’’ modification of the
Traf3 gene (Traf3flox) does not affect the expression of
Traf3 unless Cre-mediated deletion of the first two coding
exons occurs, and such a deletion leads to a Traf3 null al-
lele (Traf3D) (Figure S1A). Mice homozygous for the floxed
Traf3 allele (Traf3flox/flox) were fertile and healthy.
To delete the loxP-flanked Traf3 alleles specifically in B
lymphocytes, we used a transgenic mouse strain express-
ing Cre under the control of the endogenous Cd19 locus,
which provides a B cell-specific source of Cre (Rickert
et al., 1997). It has been previously shown that Cd19Cre
mediates deletion of loxP-flanked gene segments specif-
ically in the B cell lineage and that the deletion efficiency is
75%–80% in the bone marrow (BM) and >95% in splenic
B cells (Pasparakis et al., 2002; Rickert et al., 1997).
Traf3flox/floxCd19+/Cre mice were born at the expected
Mendelian frequencies and survive and breed normally.
We verified excision of the first two coding exons of the
Traf3 gene and the elimination of TRAF3 protein expres-
sion in splenic B cells of Traf3flox/floxCd19+/Cre mice (B-
Traf3/ mice) by genomic PCR and western-blot analy-
sis, respectively (Figure S1C and Figure 1A).
Splenomegaly and Lymphoadenopathy
with Expanded B Cell Compartments
in B-Traf3/ Mice
Adult B-Traf3/ mice exhibited greatly enlarged spleens
and lymph nodes (LNs) compared to those from
Traf3flox/flox littermate control (LMC) or wild-typemice (Fig-
ure 1B, Figure S1A, and data not shown). In contrast, the
thymus size of B-Traf3/mice was comparable to that of
LMCmice, and the spleen size of Traf3+/floxCd19+/Cre mice
was similar to that of LMC mice (data not shown). Histo-
chemical staining of LN sections revealed that B-Traf3/
mice had increased size and numbers of lymphoid follicles
(Figure S3B).
To determine which cell types were expanded in the en-
larged spleen and LNs of B- Traf3/mice, we performed
cellularity analysis by immunofluorescence staining and
flow cytometry. Proportions and absolute numbers of B
cells (B220+ or IgM+) in both spleen and LNs were mark-
edly increased, whereas the proportion of T cells (CD3+)
was reduced in B-Traf3/ mice (Figure 1C, Figure S3C,
and Table S1). Further detailed analysis of B cell sub-
sets revealed that the numbers of T2 transitional
(B220+AA4.1+IgM+CD23+ or B220+AA4.1+IgM+IgD+), fol-
licular (B220+IgM+CD21intCD23hi), and marginal zone
(B220+IgM+CD21hiCD23int or B220+IgM+CD1d+CD9+) B
cells were vastly increased in the spleen of B-Traf3/
mice (Figures 1D and 1E and Table S1). Particularly,
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TRAF3 Regulates Peripheral B Cell HomeostasisFigure 1. Expanded B Cell Compartments in Spleens and Lymph Nodes of B-Traf3/ Mice
(A) Verification of Traf3 deletion in B cells by immunoblot analysis. Splenic B cells were purified from LMC and B-Traf3/ (Traf3/) mice by negative
selection with CD43-magnetic beads. Total cellular proteins were extracted from both the purified B cells (B) and the CD43+ (mainly non-B) cells (N).
The same protein blot was first immunoblotted for TRAF3, and then it was stripped and reprobed for TRAF2, TRAF1, TRAF6, and actin. NS, non-spe-
cific band. Results shown are representative of three independent experiments.
(B) Enlarged spleen of B-Traf3/ mice. The graph depicts spleen weights (mean ± SEM, n = 10 for each group of mice).
(C) Percentages and numbers of B and T cells in spleens and LNs of LMC and B-Traf3/mice. B cells and T cells were identified by FACS analysis
with markers described in Table S1. The graph depicts the results of four independent experiments (mean ± SEM).
(D) Representative FACS histograms or contour plots of splenic B cells of LMC and B-Traf3/mice. FACS profiles were scatter-gated on single lym-
phocytes. T1, T2, follicular (FO), and marginal zone (MZ) B cell populations were identified with markers described in Table S1. Similar results were
observed in three additional experiments.
(E) Percentages (among total B cells) and numbers of splenic B cell subsets of LMC and B-Traf3/ mice. The graph depicts the results of four in-
dependent experiments (mean ± SEM). Mice analyzed were 8 to 12 weeks old.Immunity 27, 253–267, August 2007 ª2007 Elsevier Inc. 255
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cells were increased in B-Traf3/ mice, and such an
expansion of marginal zone B cells was also verified by
immunofluorescence staining of spleen cryosections
(Figure S6). Interestingly, the expression of CD21 and
CD23, two markers for peripheral B cell maturation,
were increased in both splenic and LN B cells of
B-Traf3/ mice (Figure S4). However, proportions of
B-1a (B220+CD11b+CD5+), B-1b (B220+CD11b+CD5),
and B-2 (B220+CD11b-CD23+) subsets in peritoneal la-
vages from B-Traf3/ mice were normal compared to
those from LMCmice (data not shown). In addition, thymic
T cell subsets of B-Traf3/mice were unchanged relative
to those of LMC mice (Figure S5). In summary, these re-
sults indicate that the splenomegaly and lymphadenopa-
thy of B-Traf3/ mice were due to massive expansion
of B cell compartments, and Traf3/ B cell expansion
was evident from the T2 transitional B cell stage onward.
Because TRAF3 ablation specifically occurred in the B
cell lineage but not in non-B cells, we conclude that the
B cell hyperplasia observed in B-Traf3/ mice is B cell
autonomous.
Spontaneous Germinal Center B Cells
in B-Traf3/ Mice
We examined splenic microarchitecture of B-Traf3/
mice by immunohistochemical staining and microscopy.
Consistent with flow cytometric data, B-Traf3/ mice
had enlarged white pulp with expanded B cell follicles
compared to LMC mice (Figure 2A). However, the overall
organization of B cell follicles (IgM+, blue), T cell zones
(CD3+, red), and germinal center (GC) (PNA+, green)
were otherwise normal in B-Traf3/ mice immunized
with sheep red blood cells (SRBCs) (Figure 2A). Notably,
60% (n = 10) of unimmunized B-Traf3/mice manifested
numerous spontaneous GCs in the spleen, and these
spontaneous GCs were not observed in unimmunized
LMC mice (Figures 2A–2C). Flow-cytometric analysis re-
vealed that Traf3/ splenic GC B (B220+PNA+) cells ex-
pressed increased surface IgM and IgG compared to
LMC B cells (Figure 2D) and that GC B cells are CD38low
and CD95high relative to non-GC B (B220+PNA) cells in
both LMC and B-Traf3/ mice (Figure S14). Taken to-
gether, these results suggest that some Traf3/ B cells
may be activated by endogenous antigens in mice.
Hyperimmunoglobulinemia and Enhanced
T Independent Antibody Responses
in B-Traf3/ Mice
The primary function of B cells is to produce immunoglob-
ulins. Basal serum Ig isotypes IgM, IgG2a, IgG2b, IgG3,
and IgAwere elevated 2- to 5-fold in B-Traf3/mice com-
pared to those observed in LMCmice as measured by en-
zyme-linked immunosorbent analysis (ELISA) (Figure 3A).
In contrast, basal serum titers of IgG1 and IgE were unal-
tered (Figure 3A). In response to the challenge of a T inde-
pendent antigen (T-I Ag), trinitrophenyl (TNP)-Ficoll, B-
Traf3/ mice developed higher titers of TNP-specific
IgM, IgG1, IgG2a, IgG2b, and IgG3 antibodies as com-256 Immunity 27, 253–267, August 2007 ª2007 Elsevier Inc.pared to LMC mice (Figure 3B). Interestingly, after immu-
nizationwithaTdependent (T-D)Ag, TNP-KLH,B-Traf3/
mice showed an increased TNP-specific IgM response
but a normal TNP-specific IgG1 response as compared
to the response shown by LMC mice (Figure 3C). Taken
together, these results reveal that T-I antibody responses
were increased, but the T-D IgG1 response was unaltered
in B-Traf3/ mice.
Prolonged Survival of Traf3/ Resting
Splenic B Cells Ex Vivo
Expansion of B cell compartments in secondary lymphoid
organs may result from increased output from BM, en-
hanced proliferation, or prolonged lifespan of peripheral
B cells. To evaluate which of these contributed to the
B cell hyperplasia in B-Traf3/ mice, we first analyzed
proportions and numbers of B cell precursors in BM.
Proportions and numbers of pro-B (B220+IgM-c-
Kit+CD25), pre-B (B220+IgM-c-Kit-CD25+), immature
(B220+AA4.1+IgM+IgD), and recirculating mature
(B220+AA4.1-IgM+IgD+) B cells in BM of B-Traf3/ mice
remained similar to those observed in LMC mice
(Figure S7 and Table S1). These data, together with the ev-
idence that the numbers of T1 transitional B cells were
only slightly increased (approximately 1.4 fold) in B-
Traf3/ mice (Figure 1E and Table S1), suggest that the
increase, if any, in production of immature B cells in the
BM of B-Traf3/ mice is likely to be quite modest.
We next sought to investigate the survival and prolifera-
tion capacity of freshly isolated Traf3/ resting splenic B
cells ex vivo. When cultured ex vivo with no treatment,
Traf3/ resting splenic B cells exhibited greatly ex-
panded survival capacity compared to LMC B cells
(Figure 4A). Approximately 30% of Traf3/ B cells re-
mained alive even on day 16 of culture, and BAFF treat-
ment did not further improve their survival (Figure 4A
and data not shown). Analysis of cell-cycle distribution
by propidium iodide staining and flow cytometry showed
that in sharp contrast to LMC B cells, Traf3/ B cells
did not undergo spontaneous apoptosis ex vivo even by
day 6 of culture (Figure 4B). Results from both cell-cycle
analysis and CFSE-dilution experiments demonstrated
an unaltered proliferation response in Traf3/B cells after
stimulation with CD40 or CD40 in combination with BCR
or IL-4 (Figure S8 and Figure 4C). The enhanced CD40-in-
duced proliferation response in Traf3/B cells (Figure 4A)
is likely to be secondary to their prolonged survival
(Figure 4B). Thus, our data indicate that TRAF3 deficiency
does not induce proliferation, but it can protect splenic B
cells from apoptosis and lead to prolonged survival ca-
pacity independent of BAFF.
Lack of Involvement of Soluble Factors
in Enhanced Lifespan of Traf3/ B Cells
The prolonged survival of Traf3/ B cells could not be at-
tributed to higher expression of BAFF receptors or CD40
because the expression of BAFF-R, TACI, BCMA, and
CD40 in Traf3/ resting splenic B cells, either freshly iso-
lated or after stimulation with BAFF or anti-CD40, were
Immunity
TRAF3 Regulates Peripheral B Cell HomeostasisFigure 2. Spontaneous Germinal Centers in B-Traf3/ Mice
(A) Splenic architecture of LMC and B-Traf3/ mice. Frozen sections were prepared from spleens of naive mice or mice immunized with SRBC at
11 days postimmunization, and sections were stained with PNA-FITC (green), anti-IgM-Alexa Fluor 350 (blue), and anti-CD3-PE (red).
(B) GC B cells analyzed by FACS analysis. Representative FACS contour plots of splenocytes of LMC and B-Traf3/mice are shown. Similar results
were observed in two additional experiments.
(C) Percentage of spontaneousGCB cells (B220+PNA+) of LMC and B-Traf3/mice (n = 10 for each group of mice). *, very significantly different from
LMC mice (t test, p < 0.005).
(D) Distinct expression profile of GCB cells of B-Traf3/mice. Splenocytes of naivemice ormice immunizedwith SRBC at 11 days postimmunization
were analyzed by FACS staining. The graph depicts the mean channel fluorescence (MCF) of IgM, IgD, IgG, CD23, CD38, and CD95 expression on
B220+PNA+-gated splenocytes. Data shown are the results of three independent experiments (mean ± SEM). Mice analyzed were 10 to 12 weeks old.Immunity 27, 253–267, August 2007 ª2007 Elsevier Inc. 257
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TRAF3 Regulates Peripheral B Cell HomeostasisFigure 3. Altered Antibody Responses in B-Traf3/ Mice
(A) Basal serum titers of Ig isotypes. Sera from naive LMC and B-Traf3/mice (n = 10 for each group) were tested for IgM, IgG1, IgG2a, IgG2b, IgG3,
and IgE by ELISA. Mice analyzed were 10 to 12 weeks old. (B) T-I antibody responses. Mice (8-10 weeks old, n = 10 for each group) were immunized
with the T-I Ag TNP-Ficoll in Alum, and sera were collected on day 10 after immunization. Serum titers of anti-TNP IgM, IgG1, IgG2a, IgG2b and IgG3
were analyzed by ELISA. (C) T-D antibody responses. Mice (8-10weeks old, n = 11 for each group) were immunized with the T-D Ag TNP-KLH in Alum,
and boosted on day 21 after the first immunization. Sera were collected on day 7, 14 and 28 after the first immunization. Serum titers of anti-TNP IgM
and IgG1 were measured by ELISA. Multiple serial dilutions of each serum sample were tested to ensure the readout is within the linear range of the
assay. Relative titer = A405 value x 10 x Dilution factor. TNP-specific Ig titers in pre-immune sera (with 1:100 dilution) of both littermate control and
B-Traf3/mice were below the detection limit of ELISA. *, significantly different from LMC (t test, p < 0.05); **, very significantly different from LMC
(t test, p < 0.01).identical to those detected in LMC B cells (Figure S9 and
data not shown). We also evaluated the possibility that
death-receptor-mediated apoptotic pathways may be
generally impaired in the absence of TRAF3. However,
Fas-mediated apoptosis in Traf3/ B cells was intact,258 Immunity 27, 253–267, August 2007 ª2007 Elsevier Inc.and induction of Fas expression by CD40 stimulation
was unaffected by TRAF3 deficiency (Figure S10), indicat-
ing that extrinsic apoptotic pathways are not detectably
impaired in Traf3/ B cells. In addition, results of trans-
well coculture experiments showed that coculture of
Immunity
TRAF3 Regulates Peripheral B Cell HomeostasisFigure 4. Prolonged survival of Traf3/ resting splenic B cells ex vivo
Resting splenic B cells were purified from 8- to 12- week-old LMC and B-Traf3/mice andwere cultured in the absence or presence of stimulation as
indicated.
(A) B cell survival ex vivo. The numbers of viable cells at each time point were determined by staining with Trypan blue. Data shown are results of three
independent experiments (mean ± SEM).
(B)Cell-cycle analysisbyPI stainingandFACS.RepresentativehistogramsofPI stainingareshown,andpercentageof apoptoticcells (DNAcontent<2n)
and proliferating cells (2n < DNA content% 4n) are indicated.
(C) B cell proliferation analyzed by CFSE labeling. Dashed FACS profile shows CFSE signals of freshly labeled cells, whereas solid profile shows
diluted CFSE signals of cells cultured ex vivo for 4 days in the presence of indicated stimulation. Similar results were observed in two additional
experiments.Traf3/ and LMC B cells did not prolong the survival of
LMC B cells (Figure S11) and thus exclude the possibility
that Traf3/ B cells may constitutively produce prosur-
vival cytokines (such as BAFF or IL-6). Together, these re-
sults indicate that prolonged survival of Traf3/ B cells is
due to changes in intrinsic pathways regulating B cell sur-
vival or apoptosis.Increased Nuclear NF-kB2 and Decreased
Nuclear PKCd in Traf3/ B Cells
Activation of both NF-kB1 and NF-kB2 promotes B cell
survival, and PKCd nuclear translocation induces B cell
apoptosis (Claudio et al., 2002; Mecklenbrauker et al.,
2004; Sasaki et al., 2006). We thus assessed whether
TRAF3 deficiency alters these pathways. CD40-inducedImmunity 27, 253–267, August 2007 ª2007 Elsevier Inc. 259
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TRAF3 Regulates Peripheral B Cell HomeostasisFigure 5. Increased NF-kB2 Activation and Decreased Nuclear PKCd in Traf3/ B Cells
Resting splenicBcellswerepurified from10- to12-week-old LMCandB-Traf3/miceandwere cultured exvivo in theabsenceorpresenceof 2mg/ml
anti-CD40 for indicated times.
(A) NF-kB1 activation. Total cellular lysates were immunoblotted for phosphorylated (P-) or total IkBa and then immunoblotted for actin.
(B) NF-kB2 activation and PKCd nuclear translocation. Cytosolic and nuclear extracts were immunoblotted for NF-kB2 (p100-p52), RelB, and PKCd
and then immunoblotted for actin (used as loading control for cytosolic proteins) or YY1 (used as loading control for nuclear proteins).
(C) Quantitation of nuclear p52, RelB, and PKCd protein amounts. Nuclear p52, RelB and PKCd bands on immunoblots (right panel of [B]) were quan-
titated with a low-light imaging system, and the results were presented graphically. The amount of p52, RelB, or PKCd in each lane was normalized to
the intensity of the corresponding YY1 band. The graph depicts the results of three independent experiments (mean ± SEM).phosphorylation and degradation of IkBa, the hallmark of
NF-kB1 activation, was similar in Traf3/ and LMCBcells
(Figure 5A). Similarly, CD40-induced phosphorylation of
JNK, p38, and ERK was unaltered in Traf3/ B cells
(Figure S12). Activation of NF-kB2 requires the processing
of the inactive precursor p100 to p52 in the cytosol, and
this processing allows the p52-RelB dimer to translocate
into the nucleus for activation of transcription of target
genes. Ex vivo culture of purified LMC B cells for 24 hr,
equivalent to deprivation of endogenous B cell survival
factor(s) such as BAFF (Claudio et al., 2002), resulted in
an increase in the cytosolic p100 amount and a decrease
in nuclear p52 and RelB (Figures 5B and 5C). In contrast,
BAFF stimulation decreased the cytosolic p100 but
sharply increased nuclear p52 and RelB in LMC B cells.
However, such changes in cytosolic p100 or nuclear p52
and RelB amounts induced by deprivation of survival fac-
tors or BAFF stimulation were not observed in Traf3/ B
cells. These cells did remain responsive to CD40 engage-
ment, which further increased nuclear p52 and RelB
amounts similar to those observed in LMC B cells. Inter-
estingly, Traf3/ B cells also displayed lower amounts260 Immunity 27, 253–267, August 2007 ª2007 Elsevier Inc.of nuclear PKCd compared to LMC B cells, although the
amounts of cytosolic PKCd were comparable (Figures
5B and 5C). Thus, Traf3/ B cells exhibited markedly in-
creased constitutive activation of NF-kB2 and decreased
PKCd nuclear translocation, and both these effects en-
hance the survival capacity of these cells.
Independence of Traf3/ B Cell Hyperplasia
on BAFF or APRIL Signaling
To address whether TRAF3 functions as a downstream
negative regulator of BAFF signals for inhibition of periph-
eral B cell survival, we examined the effects of in vivo ad-
ministration of TACI-Ig, a soluble fusion protein that
blocks both BAFF and APRIL from binding to their recep-
tors (Gross et al., 2001), in B-Traf3/ and LMC mice.
Although administration of TACI-Ig effectively reduced
the spleen weight and depleted B cells in spleen and
LNs of LMC mice, it was unable to reduce the spleen
weight or B cell numbers in spleen and LNs of B-Traf3/
mice (Figure 6). Analysis of B cell subsets indicated that
TACI-Ig treatment decreased the proportions of mature
B (B220+AA4.1) and especially marginal zone B
Immunity
TRAF3 Regulates Peripheral B Cell HomeostasisFigure 6. Independence of Traf3/ B Cell Hyperplasia from BAFF and APRIL Signaling
LMC and B-Traf3/ mice (10 weeks old, n = 2 for each group) were i.p. injected with TACI-Ig or a control human Ig Fc (Hu Ig).
(A) Unreduced spleen weight of B-Traf3/mice after in vivo administration of TACI-Ig. The graph shows the results of two independent experiments
(mean ± SE).
(B) Failure of TACI-Ig to decrease the percentages and numbers of B cells in spleen and LNs of B-Traf3/mice. B and T cells were identified by FACS
analysis with B220 and anti-CD3. The graph depicts the results of two independent experiments (mean ± SE).
(C) Representative FACS histograms or contour plots of splenocytes and LN cells after TACI-Ig or Hu Ig administration. FACS profiles were scatter-
gated on single lymphocytes. Similar results were observed in a second experiment.Immunity 27, 253–267, August 2007 ª2007 Elsevier Inc. 261
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TRAF3 Regulates Peripheral B Cell HomeostasisFigure 7. Autoimmune Manifestations in B-Traf3/ Mice
(A) DsDNA autoantibodies in sera of B-Traf3/ mice. Sera from naive LMC and B-Traf3/ mice (n = 10 for each group) were tested for dsDNA
autoantibodies by ELISA. Mice analyzed were 10 to 12 weeks old. **, highly significantly different from LMC (t test, p < 0.001).
(B) Lymphocyte infiltrations in kidney and liver of B-Traf3/mice. Microsections of kidneys and livers were stained with hematoxylin and eosin, and
representative micrographs of LMC and B-Traf3/ mice are shown for comparison.
(C) Immune-complex deposition in kidney of B-Traf3/ mice. Cryosections of kidneys were blocked and stained with anti-C3-FITC (green, micro-
graphs shown in the left panel) and anti-IgG (H+L)-PE (red, micrographs shown in the middle panel). The right panel shows the merged C3 and
IgG (H+L) staining, and yellow color indicates colocalized staining. Mice analyzed in (B) and (C) were 9 to 12 months old, and similar results were
observed in two additional experiments.(B220+IgM+CD21hiCD23int or B220+IgM+CD1d+CD9+)
cells in LMC mice, but not in B-Traf3/ mice (Figure 6C).
These data indicate that Traf3/ B cell hyperplasia does
not require BAFF or APRIL binding, suggesting that
TRAF3 may constitutively inhibit NF-kB2 activation and
promote PKCd nuclear translocation to induce spontane-
ous apoptosis in peripheral B cells.
Autoimmune Manifestations in B-Traf3/ Mice
In light of the notion that prolonged survival of B cells may
contribute to autoimmune diseases (Gauld et al., 2006;262 Immunity 27, 253–267, August 2007 ª2007 Elsevier Inc.Mackay and Kalled, 2002), the spontaneous GC formation
in B-Traf3/ mice (Figure 2) prompted us to evaluate
whether these mice develop autoimmune diseases. Inter-
estingly, 80% (n=10) of B-Traf3/mice already displayed
dsDNA autoantibodies in sera at an early age (10–12
weeks), and these autoantibodies were not detected in
any LMC mice (n = 10) (Figure 7A and Figure S13). All
aged B-Traf3/ mice examined (n = 4, 9 to 12 months
old), but none of LMC mice (n = 4), had dsDNA autoanti-
bodies in sera (data not shown). Subsequent histopatho-
logical examination revealed that three out of the four
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tained lymphocyte infiltrates at multiple locations in kidney
and liver (Figure 7B and data not shown). Furthermore,
these three aged B-Traf3/mice exhibited immune-com-
plex deposition in kidney as evidenced by the colocalized
mesangial staining of IgG (H+L) and complement 3 (C3) at
glomeruli. Such colocalized staining was not detected in
any of the LMC mice (Figure 7C). Thus, specific ablation
of TRAF3 in the B cell lineage can be sufficient for inducing
autoimmune manifestations on the B6 X 129 genetic
background.
DISCUSSION
To circumvent the limitations posed by the early lethality of
Traf3/mice (Xu et al., 1996), we produced and validated
Traf3flox/flox mice to allow precise spatial and temporal ab-
lation of TRAF3 expression in the whole animal. This
model will be valuable in elucidating the physiological
function of TRAF3 in various cell lineages and develop-
mental stages. Our initial characterization of this model re-
vealed a critical role for TRAF3 in inhibiting B cell survival in
secondary lymphoid organs and raises the intriguing pos-
sibility that TRAF3 is involved in the regulation of self-tol-
erance.
B-Traf3/mice exhibited B cell expansion from the T2
transitional stage onward, leading to splenomegaly and
lymphadenopathy, hypergammaglobulinemia, and auto-
immunity, all of which are remarkably similar to the pheno-
types of BAFF-transgenic mice and PKCd-deficient mice
(Gross et al., 2000; Khare et al., 2000; Mackay et al.,
1999; Mecklenbrauker et al., 2004; Mecklenbrauker
et al., 2002; Miyamoto et al., 2002). Conversely, A/WySnJ
mice (carrying anaturally occurringmutation in theBAFF-R
gene) and mice deficient in BAFF, BAFF-R, or NF-kB2
display specific B cell loss from the T2 transitional stage
onward in peripheral lymphoid organs (Franzoso et al.,
1998; Schiemann et al., 2001; Shulga-Morskaya et al.,
2004; Thompson et al., 2001). Moreover, Traf3/ B cells
showed vastly prolonged survival ex vivo, markedly in-
creased constitutive activation of NF-kB2, and decreased
PKCd nuclear translocation independent of BAFF. These
observations led us to test the hypothesis that TRAF3
functions as a downstream negative regulator of BAFF
and BAFF-R signaling. However, in vivo administration of
TACI-Ig, a potent blocker of BAFF and APRIL signals,
failed to deplete peripheral B cells in B-Traf3/ mice.
Thus, it is more likely that TRAF3 constitutively inhibits
NF-kB2 activation and promotes PKCd nuclear transloca-
tion to induce spontaneous apoptosis in peripheral B
cells. In support of this possibility, a previous study pro-
vided in vitro evidence that TRAF3 constitutively targets
NIK, an upstream kinase required for the activation of
NF-kB2, for ubiquitination and proteosome-mediated
degradation (Liao et al., 2004). Although we could not re-
producibly detect NIK protein in Traf3+/+ or Traf3/ B
cells either in the absence or presence of the proteosome
inhibitor MG132 (data not shown), a recent study reported
that the amount of NIK protein is increased in Traf3/ Bcells and MEFs (He et al., 2006), further suggesting that
TRAF3 may constitutively target NIK for degradation to
inhibit NF-kB2 activation. How TRAF3 constitutively pro-
motes PKCd nuclear translocation remains to be
determined.
In this study, we extended our findings obtained with
Traf3/ B cell lines that CD40-induced NF-kB1, p38,
and ERK activation is not affected by TRAF3 deficiency
(Xie et al., 2004) to Traf3/ splenic B cells. However,
CD40-induced JNK activation is increased in Traf3/ B
cell lines (Xie et al., 2004) but appears to be normal in
Traf3/ splenic B cells. This difference may be due to
the different cellular context of B cell lines versus primary
splenic B cells. One possibility is that transformed B cell
lines may carry mutations in certain genes, whose altered
functions may make CD40-induced JNK activation more
sensitive to the loss of TRAF3. Another possibility is that
because Traf3/ splenic B cells developed from pro-B,
pre-B, and immature B cells in the absence of TRAF3,
they may adjust the expression of relevant genes to coun-
teract the deficiency of TRAF3, which might otherwise be
detrimental to the development of B cells. Thus, the cell
linesmay also reflect the effect of TRAF3deletion only after
B cells have completely matured. Both findings may have
physiological relevance: Splenic B cellsmay reflect the sit-
uation of altered development in the absence of TRAF3
function,whereasBcell linesmay represent the responses
in the case of oncogenic transformation, or loss of TRAF3
after completeB cellmaturation. In this regard, it should be
noted that the expression of TRAF2 is unaltered in Traf3/
B cell lines (Xie et al., 2004) but is increased in Traf3/
splenic B cells (Figure 1A). A similar upregulation of
TRAF3 expression was observed in Traf2/ splenic B
cells (Grech et al., 2004). Interestingly, conditional Traf2/
mice also display expandedBcell compartments in spleen
and LNs, and Traf2/ B cells also show increased consti-
tutive NF-kB2 activation ex vivo (Grech et al., 2004). Thus,
TRAF2 and TRAF3may have redundant function in inhibit-
ing constitutive NF-kB2 activation and B cell survival, and
upregulation of either of these TRAF molecules may par-
tially compensate for the loss of the other.
TheBcell is thecentral player in humoral immunity. Inter-
estingly, we observed that basal serum titers of various Ig
isotypes were generally elevated in B-Traf3/ mice, with
the exception of IgG1 and IgE. Similarly, antibody re-
sponses, including IgM and all IgG isotypes, to a T-I Ag
were increased in B-Traf3/ mice. Because antibody re-
sponses to TNP-Ficoll are mainly mediated by MZ B cells
(Pillai et al., 2005), the increased Ig responses toTNP-Ficoll
immunization are consistent with the vastly expanded MZ
B cells in these mice. However, in response to the T-D Ag
TNP-KLH, althoughTNP-specific IgMwas increased, IgG1
was not increased accordingly. Considering that mature B
cells, including follicular andMZBcells, weremarkedly ex-
panded in B-Traf3/mice, it is perplexing that thesemice
displayed neither an increase in the T-D IgG1 response nor
an elevation in basal serum IgG1 or IgE titers. It is known
that isotype switching to both IgG1 and IgE is regulated
by CD40 and IL-4 (Stavnezer and Amemiya, 2004). OneImmunity 27, 253–267, August 2007 ª2007 Elsevier Inc. 263
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Because IgG1 is the major antibody produced in T depen-
dent responses to bacterial pathogens and soluble protein
antigens in mice (Stavnezer and Amemiya, 2004), lack of
increase of basal serum IgG1 titer may partially reflect
the lack of increase in T dependent IgG1 responses in B-
Traf3/ mice. Notably, previous studies indicate that
CD21 and CD23 play a modulatory role in antibody re-
sponses (Haas et al., 2002; Texido et al., 1994; Yu et al.,
1994). Thus, it is also possible that the enhanced expres-
sion of CD21 and CD23 on B cells may contribute to the
serological phenotype of B-Traf3/mice.
Increasing evidence suggests that prolonged survival of
B cells contributes to autoimmune diseases (Gauld et al.,
2006; Mackay and Kalled, 2002). Peripheral self-tolerance
is induced through anergy, defined as functional inactiva-
tion of autoreactive B cells (Gauld et al., 2006). Prolonged
survival of anergic B cells can lead to autoimmunity, simply
by providing a greater opportunity for anergic B cells to be
recruited to an immune response (Gauld et al., 2006;
Mackay and Kalled, 2002). Interestingly, anergic B cells
have increased dependence onBAFF for survival and can-
not compete with normal B cells for a limiting source of
BAFF (Gauld et al., 2006; Lesley et al., 2004). Thus, thepro-
longed BAFF-independent survival capacity of Traf3/ B
cells may predispose B-Traf3/mice to develop autoim-
mune reactivity. Indeed, themajority of B-Traf3/mice al-
ready exhibited numerous and large spontaneous splenic
GCs in the absence of immunization and developed
dsDNA autoantibodies in the serum by the age of 10–12
weeks. Furthermore, aged B-Traf3/mice developed ad-
ditional autoimmunemanifestations, including lymphocyte
infiltration in kidney and liver, and immune-complex depo-
sition in kidney. Thus, specific deletion of TRAF3 in B cells
appears to be sufficient for inducing autoimmune alter-
ations in mice. However, it should be noted that B-
Traf3/ mice had a mixed genetic background of B6 X
129 and that epistatic interactions between the B6 and
129genomeshave important impacts onsystemic autoim-
mune manifestations (Manderson et al., 2004; McDonnell
et al., 1989; Strasser et al., 1991; Wakeland et al., 2001).
Thus, the mixed genetic background of B6 X 129 may
make the mice more sensitive to the loss of TRAF3 and
prone toautoimmune alterations.Nevertheless, our results
indicate that TRAF3 deficiency can be a predisposing
genetic factor to autoimmune diseases in mice.
Extended lifespan of B cells and B cell hyperplasia have
been associated with B leukemiagenesis and B lympho-
magenesis (Cory et al., 2003; Mackay and Tangye, 2004;
Packham and Stevenson, 2005). Whether B-Traf3/
mice have increased propensity to develop lymphomas
awaits investigation. Nonetheless, prolonged survival of
Traf3/ B cells could predispose them to transformation
in response to additional oncogenic events, such as viral
infections, chronic inflammation, mutations, or chromo-
somal translocations involving oncogenes or tumor sup-
pressor genes. Consistent with this, elevated serum
BAFF has been detected in humans with autoimmune dis-
eases as well as B cell malignancies (Mackay and Tangye,264 Immunity 27, 253–267, August 2007 ª2007 Elsevier Inc.2004). Caused by chromosomal translocations, constitu-
tively activated mutant forms of NF-kB2 have also been
detected in patients with B lymphomas (Karin et al.,
2002). It would thus be interesting to investigate whether
inactivating mutations of the Traf3 gene or decreased ex-
pression of TRAF3 occur in human patients with autoim-
mune diseases as well as B leukemias or lymphomas.
The new mouse model presented here suggests that spe-
cifically enhancing TRAF3 activity or expression in B cells
may be of therapeutic value in combating these human
diseases.
EXPERIMENTAL PROCEDURES
Generation of Conditional Traf3/Mice
Traf3+/flox mice were generated in accordance with standard protocols
as detailed in the Supplemental Experimental Procedures and were in-
terbred for generation of Traf3flox/flox mice. Traf3flox/flox mice were
crossed with Cd19Cre/Cre mice (Rickert et al., 1997) (Jackson Labora-
tory) for generation of Traf3+/floxCd19+/Cre mice, which were subse-
quently backcrossed with Traf3flox/flox mice for generation of
Traf3flox/floxCd19+/Cre (B-Traf3/) mice. Deletion of exons 1 and 2 of
the Traf3 gene in splenic B cells was detected by genomic PCR with
primers U7 and BT6 (Figure S1C). B-Traf3/mice that were analyzed
had a mixed genetic background between 129/SvJ and C57BL/6, and
littermates were used as controls for all experiments. All mice were
kept in specific pathogen-free conditions in the Gene Targeting Core
Facility at the University of Iowa and were used in accordance with
NIH guidelines and under an animal protocol approved by the Animal
Care and Use Committee of the University of Iowa.
Primers, Antibodies, Reagents, and Methods
for Supplemental Figures
Details of primers, Abs, reagents, and methods for supplemental fig-
ures are described in the Supplemental Experimental Procedures.
Flow Cytometry
Single-cell suspensions weremade from the spleen, LNs, thymus, BM,
and peritoneal lavages. Erythrocytes from spleen were depleted with
ACK lysis buffer. Cells (0.5 3 106) were then blocked with rat serum
and FcR blocking Ab (2.4G2) and incubated with various Abs conju-
gated to FITC, PE, PerCP, or Cy5 for multiple color fluorescence sur-
face staining. For cellularity analysis, cell-surface markers examined
include CD45R (B220), CD3, AA4.1, c-Kit, CD25, CD1d, CD9, CD19,
CD21, CD23, CD5, IgM, IgD, CD38, CD43, CD4, CD8, CD11b, Gr-1,
andMHC class II (I-A/I-E) as indicated in the figures and Table S1. List-
mode data were acquired on a FACSVantage (Becton Dickinson) with
Cell Quest software. The results were analyzed with FlowJo software
(TreeStar). FSC-SSC gating for single lymphocytes, excluding cell
aggregates, small erythrocytes, and dead cell debris, was used for an-
alyzing flow-cytometric data.
Hematoxylin-Eosin Staining of Tissues
Mouse LNs, kidney, and liver were fixed in 10% neutral formalin, then
processed and embedded in paraffin. Microsections (5 mm) of paraffin
blocks were prepared with a microtome (HM 355, Microm) and were
stained with hematoxylin and eosin with an automated slide stainer
(Sakura DRS 601 Diversified Stainer, Sakura). Stained slides were
mounted with Solvent 100 mounting media, and bright-field micro-
graphs of stained sections were taken with a microscope (Olympus
BX-51, Olympus America) fitted with an Olympus DP70 camera (Olym-
pus America).
Immunohistochemistry
Spleens were harvested from naive mice or mice immunized i.p. with
0.1 ml of 10% SRBC in PBS for 10 days. Kidneys were collected
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20 min, embedded with OCT compound, and snap frozen in liquid N2.
Frozen sections (8–10 mm) were prepared with a cryostat (HM505E,
Microm) and fixedwith cold acetone. Rehydration, blocking, and stain-
ing of sections were carried out as described (Stunz et al., 2004).
Spleen sections were stained with FITC-PNA, Alexa Fluor 350-anti-
mouse IgM Ab, and PE-anti-mouse CD3 Ab so that splenic architec-
ture could be determined, or sections were stained with FITC-anti-
mouse MOMA-1 Ab and PE-B220 for visualization of MZ B cells.
Kidney sections were stained with FITC-anti-mouse C3 Ab and PE-
anti-mouse IgG (H+L) Ab. Stained slides were mounted with Vector-
Shield and observed on a fluorescence microscope (Olympus BX-60,
Olympus America) fitted with a Sensys camera (Photometrics). Images
were analyzed with ImagePro4.5 software (Media Cybernetics).
Immunizations and ELISAs
Basal-serum titers of various Ig isotypes were analyzed by ELISA as
previously described (Stunz et al., 2004). In the IgE-specific ELISA,
capture mAb was EM95, and detection Ab was Alkaline phosphatase
(AP)-conjugated goat anti-mouse IgE Ab. All the other capture Abs and
AP-conjugated detection Abs were polyclonal goat Abs, including Abs
specific for mouse IgM, IgG1, IgG2a, IgG2b, IgG3, and IgA. Plates
were read on a Versamax plate reader (Molecular Devices), and results
were analyzed with SoftMax Pro 4.0 software. Standard curves were
included on each plate in accordance with purified standards (South-
ern Biotechnology Associates) for each Ig isotype.
For T-I antibody responses, mice were immunized i.p. with 50 mg of
TNP-Ficoll (Biosource Technologies) precipitated in alum. Sera were
collected on day 10 after immunization. TNP-specific Abs in sera
were measured with the use of ELISA plates coated with TNP38-
conjugated bovine-serum albumin. Bound Abs were detected with
AP-conjugated goat anti-mouse IgM, IgG1, IgG2a, IgG2b, or IgG3, re-
spectively. For T-D antibody responses, micewere immunized i.p. with
100 mg of TNP-KLH (Biosource Technologies) precipitated in alum and
boosted with 100 mg of TNP-KLH in alum on day 21. Sera were col-
lected on day 7, 14, and 28 after the first immunization. Serum titers
of anti-TNP IgM and IgG1 were measured by ELISA as described
above. For TNP-specific IgG1 or IgG2a, standard curves were deter-
mined on each plate with serial dilutions of purified standards
(BD PharMingen). For TNP-specific IgM, IgG2b, or IgG3, standard
curves were determined on each plate with serial dilutions of a stan-
dard serum. Multiple 1:5 or 1:10 serial dilutions of each serum sample
were examined in each TNP-specific Ig isotype ELISA, and the range
of the dilution factors tested is from 1:100 to 1:1000000. Each standard
curve contained 11 dilution points, and in all cases, the coefficient of
determination for the standard curve (r2) was >0.98. The dilution factor
that gave A405 (O.D.405 nm) values within the linear range (0.11.5) of
standard curves of ELISA was used for calculating the concentrations
of TNP-specific IgG1 and IgG2a or the relative titers of TNP-specific
IgM, IgG2b, and IgG3. Relative titers were calculated according to
the formula ‘‘relative titer = A405 value 3 10 3 dilution factor,’’ and
therefore reflect the relative concentrations of each TNP-specific Ig
isotype in arbitrary units.
Splenic B Cell Purification
Splenic B cells and non-B cells were separated with anti-mouse CD43-
coated magnetic beads and a MACS separator (Miltenyi Biotec) in ac-
cordance with the manufacturer’s protocols. For purification of resting
splenic B cells, high-density resting splenocytes were first isolated by
density gradient centrifugation through a 60%:65%:85% Percoll gra-
dient. Resting lymphocytes at the interface between 65% and 85%
Percoll were collected, and resting B cells were further purified by
negative selectionwith anti-mouseCD43magnetic beads according to
the manufacturer’s protocols. The purity of isolated populations was
monitored by FACS analysis with Cy5-anti-B220, FITC-anti-IgM and
PE-anti-Fas, and cell preparations of >90%purity were used for further
experiments. Purified resting splenic B cells were cultured in mouse-
culture medium (RPMI 1640 medium supplemented with 5% FCS,10 mM b-mercaptoethanol, 10 mM HEPES [pH 7.55], 1 mM sodium
pyruvate, 2 mM L-glutamine, and 0.1 mM nonessential amino acids).
Survival Assay and Cell-Cycle Analysis
Purified resting splenic B cells (0.5 3 106/ml/well) were cultured in 24-
well plates in the absence or presence of 0.5 mg/ml BAFF or 2 mg/ml of
anti-mouse CD40 Ab (HM40-3) at 37C. Cells were fed with fresh me-
dium containing the appropriate stimulation every 4 days. At each time
point, the number of viable cells was determined by staining with Try-
pan blue. For PI staining, cells were fixed with an equal volume of ice-
cold 70% ethanol. PI staining was performed as previously described
(Catlett et al., 2001), and DNA content was quantified with a benchtop
FACScan (Becton Dickinson). Labeling of B cells with CFSE (Molecular
Probes) for proliferation analysis was performed in accordance with
the manufacturer’s instructions. Labeled cells were cultured in the ab-
sence or presence of 2 mg/ml of anti-mouse CD40 (HM40-3) alone or in
combinationwith 10mg/ml of anti-mouse IgM (Fab’) or 100 ng/ml of IL-4
at 37C for 4 days. Cells were then fixed, and the decline in CFSE
fluorescence as a measure of proliferation was determined by FACS
analysis.
Immunoblot Analysis
For detection of TRAF3 expression in B cells versus non-B cells, puri-
fied CD43+ and CD43 splenocytes were directly lysed as previously
described (Xie and Bishop, 2004). For detection of the activation of
NF-kB1 or MAP kinases, purified resting splenic B cells were cultured
in the absence or presence of 2 mg/ml of anti-mouse CD40 (HM40-3) at
37C for various time periods as indicated in the figures, and total cel-
lular lysates were prepared. For detection of nuclear translocation of
NF-kB2 and PKCd, purified resting splenic B cells were cultured in
the absence or presence of 0.5 mg/ml BAFF or 2 mg/ml of anti-mouse
CD40 (HM40-3) at 37C for 24 hr. Cytosolic and nuclear extracts
were prepared as described (Xie et al., 2006). Immunoblot analysis
was performed with various antibodies as previously described (Xie
and Bishop, 2004). Protein bands on immunoblots were quantitated
with a low-light imaging system (LAS-1000, FUJIFILM Medical Sys-
tems USA).
In Vivo Administration of TACI-Ig
Mice (10 weeks old) were injected i.p. with 100 mg of TACI-Ig (R&DSys-
tems) or a control Ig (human Ig Fc) three times a week for 15 days.
Detection of dsDNA Autoantibodies
Sera from naive mice were tested for autoantibodies with ELISA kits
detecting dsDNA Abs (Alpha Diagnostic) in accordance with the man-
ufacturer’s protocols. Standards and negative and positive control
sera provided by the manufacturer were run concurrently with the un-
known samples. The specificity of dsDNA autoantibodies detected in
B-Traf3/ mice was verified by a second assay with Crithidia luciliae
dsDNA substrate slides (The Binding Site) as previously described
(Stunz et al., 2004).
Statistics
For direct comparison of spontaneous GC B cells and Ig isotype titers
of LMC and B-Traf3/ mice, statistical significance was determined
with the unpaired t test for two-tailed data. All p values less than
0.05 are considered significant, and p values less than 0.01 are consid-
ered very significant.
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